ATRA Atara Biotherapeutics
- 8.075
- +0.415+5.42%
- 8.200
- +0.125+1.55%
Atara Biotherapeutics News
Atara Biotherapeutics Analyst Ratings
Atara Biotherapeutics: Hold Rating Maintained Amid Financial Shortfalls and Regulatory Uncertainties
H.C. Wainwright Maintains Atara Biotherapeutics(ATRA.US) With Hold Rating
Atara Biotherapeutics (ATRA) Gets a Hold From Stifel Nicolaus
Atara Biotherapeutics Analyst Ratings
Mizuho Securities Upgrades Atara Biotherapeutics(ATRA.US) to Buy Rating, Cuts Target Price to $18
CCORF Maintains Atara Biotherapeutics(ATRA.US) With Buy Rating, Maintains Target Price $13
Atara Biotherapeutics Analyst Ratings
CCORF Maintains Atara Biotherapeutics(ATRA.US) With Buy Rating, Maintains Target Price $13
Atara Biotherapeutics Receives Buy Rating Amidst Positive FDA Review and Solid Financial Outlook
Atara Biotherapeutics Analyst Ratings
Goldman Sachs Maintains Sell on Atara Biotherapeutics, Lowers Price Target to $11
Atara Biotherapeutics Hold Rating Based on Promising Preclinical Data and Awaited Clinical Trials
Stifel Nicolaus Sticks to Its Hold Rating for Atara Biotherapeutics (ATRA)
Atara Biotherapeutics Analyst Ratings
Atara Biotherapeutics: A Balanced Hold Amidst FDA Approval Prospects and Valuation Uncertainties
Analysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH), Atara Biotherapeutics (ATRA) and Nkarta (NKTX)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cytek Biosciences (CTKB), Elanco Animal Health (ELAN) and Atara Biotherapeutics (ATRA)
Buy Rating Affirmed for Atara Biotherapeutics on Strong Pipeline and Financial Health
Atara Biotherapeutics Analyst Ratings
Analysis
Price Target
No Data
No Data